GE HealthCare Technologies (GEHC) - 2023 Q2 - Earnings Call Presentation

Q2 2023 Financial Performance - Total revenue reached $4.8 billion, reflecting a 6% year-over-year increase[27] - Organic revenue growth was 9% year-over-year[29] - Adjusted EBIT margin was 14.8%, a decrease of 120 basis points year-over-year, but up year-over-year excluding post-spin cash outflows[28] Segment Performance - Imaging revenue was $2.6 billion, with 9% organic revenue growth[32] - Ultrasound revenue was $839 million, with 3% organic revenue growth[93] - Patient Care Solutions (PCS) revenue was $770 million, with 9% organic revenue growth[54] - Pharmaceutical Diagnostics (PDx) revenue was $568 million, with 20% organic revenue growth[82] Orders and Cash Flow - Organic orders growth was 6%[89] - Free Cash Flow (FCF) was negative $136 million, but up year-over-year excluding standalone interest and incremental post-retirement benefit payments[57] Guidance - The company raised its full-year 2023 organic revenue growth guidance to 6% to 8%[45] - Adjusted EPS guidance was raised to $3.70 - $3.85, representing growth of 9% to 14%[45] - Adjusted EBIT margin is reaffirmed in the range of 15% to 15.5%[41] - Free cash flow conversion is reaffirmed at 85%+ [41]